54 Biotech companies
Index

* *in the planning stage*

Area of activity

genopole®
SUCCEED TOGETHER IN BIOTECHNOLOGY

Biomedicine / Healthcare

Bio-informatics / Informatics

Chemistry

Agro-industry

Medical Instrumentation

ABAG

Biomedicine / Healthcare

CEO
Marc BOURLIOUX

CONTACT DETAILS
Technopolis, Bâtiment 2
17, avenue du Parc
F-91380 CHILLY-MAZARIN

PHONE +33 1 69 79 64 80
FAX +33 1 69 09 79 34
E-MAIL abag@wanadoo.fr

DATE OF FOUNDING
28th Nov. 2001

BUSINESS SECTOR
• **In vitro diagnostics.**

FIELD OF ACTIVITY
• **Infectious disease.**

DESCRIPTION
• AbAg is developing the concept of “syndrome-based, multiparameter serological profiling” for infectious disease diagnosis.

AbAg is creating its own portfolio of innovative, recombinant antigens and has established a collaboration with the Biochip Laboratory at **CEA Grenoble** (the French Atomic Energy Commissariat) in order to develop the **“Capucine”** array as the company’s innovative, multiplex format.

ACRITER

Medical Instrumentation

MANAGING PARTNERS
Catherine BURNOUF
Maria CHOVET
Frédéric DOC

CONTACT DETAILS
Immeuble Le Magellan
7, rue Montespan
F-91024 EVRY cedex

PHONE +33 1 69 47 60 45
E-MAIL
info@acriter-consulting.com
WEB SITE
www.acriter-consulting.com

DATE OF FOUNDING
21st June 2004

BUSINESS SECTOR

• provision of consulting services to organizations and continuing education courses to collaborators.

FIELD OF ACTIVITY

• Support for drug discovery-oriented organizational development.

DESCRIPTION

• We provide consulting and training activities which are highly suited to specific client needs and which recognize the constraints of the global drug discovery lifecycle:
- a process approach: helping to develop and implement a continuous improvement approach for ensuring the quality and productivity of corporate research activities.
- research project management: promoting the development and implementation of this specific organizational process as a key success factor in building a results-oriented corporate culture.
- learning from experience: contributing to corporate information system development in order to promote collaborative working and optimize knowledge management.

• We arrange training sessions in three fields:
- the drug discovery process: providing an intensive overview of the global R&D process, from idea to market:
  * understanding the main successive phases and subsequent links.
  * analyzing constraints and requirements.
  * outlining the impact of the various stakeholders' roles and responsibilities as part of a global process.
- research project management: applying project management knowledge, tools and methods with particular relevance to the specific features of research, scientists' requirements and a results-oriented corporate culture for optimizing R&D productivity.
- end-user representative assistance in projects on research-dedicated information system development: educating scientists with precise, concrete knowledge for supporting IT tool design projects.

Enterprise

AISA Therapeutics sarl

Biomedicine / Healthcare

BUSINESS SECTOR

Biomedicine/human and animal healthcare (therapeutic research).

FIELD OF ACTIVITY

AISA therapeutics aims at developing new anti-inflammatory molecules based on the modulation/inhibition of vascular permeability. Potential applications include chronic inflammatory diseases such as rhumatoid arthritis, obesity, degenerative diseases, aging and metastatic spreading.

DESCRIPTION

• AISA therapeutics was incorporated with the objective of developing anti-inflammatory molecules that target the vascular endothelium. About ten molecules have been identified using a novel in vitro cell model, and four of these are already claimed in a patent. One of the lead molecules is at the pre-clinical stage. Studies have shown the molecule's excellent performance when compared to NSAID anti-inflammatory drugs for an indication of colitis. Other molecules will be developed in a cystic cancer model. In addition to human healthcare (which remains the absolute priority), AISA therapeutics is keen to explore other pathways where the inflammatory process plays a key role, particularly in animal diseases.

DIRECTOR

Patrizia d'ALESSIO

CONTACT DETAILS

Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91000 EVRY

PHONE +33 1 45 59 51 46
E-MAIL dalessio@vjf.inserm.fr

DATE OF FOUNDING

19th Oct. 2005

AOK ENGINEERING

Medical Instrumentation

AOK Engineering

DIRECTOR
Antoine KLOTZ

CONTACT DETAILS
93, rue Henri Rochefort
F-91000 EVRY

PHONE +33 1 30 90 95 13
E-MAIL aklotz@aok-e.com
WEB SITE www.aok-e.com

DATE OF FOUNDING
10th Oct. 1996

BUSINESS SECTOR
Electronic Medical Devices.

FIELD OF ACTIVITY
Development and sale of medical devices for non-invasive emulation of the vascular system.

DESCRIPTION
• The Products: **DataVein®** (CE marked), Electrodes, **VeinoCard®** for external, electrical, vascular stimulation.

AOK subcontracts its manufacturing but develops, clinically tests, markets and sells its products either directly or through alliances.

The **DataVein®** pulse generator produces vasodilation of all blood vessels located between the two active electrodes, strengthens vessel tissues, increases blood speed and flow and prompts the natural generation of nitric oxide (NO) which induces vessel healing. It also induces the natural release of fibrinolytic and anti-aggregant factors, without modifying coagulation factors or being hemorrhagic in any way all. This is a technological breakthrough which brings considerable cost/benefit advantages relative to medications. It is successful where no other treatments work.

Potential markets cover inpatient and outpatient medicine, home care, physiotherapy and some general public markets. The device is covered by European and US patents and also benefits from «method of use» protection in the USA.

AOK will focus on well-defined fields where drugs are unsatisfactory or not of use: arterial diseases (whether related to diabetes or other causes), lymphedemas and other cardiac-related edemas.

The **DataVein®** technology uses only the human body's own resources. It is more efficient than medication, safe, requires no medical tests, can be used for the vast majority of patients and has almost no counter-indications. These breakthroughs make the device stand out from its competitors and explain the DataVein's® rapid acceptance by the medical community.

ATRAGENE bioinformatics

Bio-informatics and Informatics

atragene Research Informatics

DIRECTOR
Alain MALPERTUY

CONTACT DETAILS
10, allée des Champs Elysées
F-91042 EVRY Cedex

PHONE +33 1 60 78 34 11
E-MAIL contact@atragene.com
WEB SITE www.atragene.com

DATE OF FOUNDING
20th Nov. 2001

BUSINESS SECTOR

• Discovery Informatics, Biointegration®, IT R&D, Bioinformatics, Cheminformatics.

FIELD OF ACTIVITY

• ATRAGENE is a provider of innovative cost-effective IT solutions for the life sciences industry in the key areas of information and software integration and management.

DESCRIPTION

• Over the last few years, research informatics has emerged as an essential technology for enhancing R&D productivity in the biotech and pharmaceutical industries. From drug candidate selection to drug target validation, research teams require state-of-the-art informatics architecture to capture, retrieve, visualize and analyze data.

ATRAGENE is a service-oriented company. Our offer includes consulting assignments to assist research organizations in the definition, development and deployment of systems and/or IT architectures. We also provide ATRAGENE resources for short or long term contracts.

ATRAGENE areas of expertise:
• Design and implementation of systems for integrating, visualizing and mining biological and chemical information in order to explore and discover hidden or unexpected relationships.
• Development of tailor-made software to meet particular technology and business requirements.
• Design and implementation of powerful informatics architectures for capturing, managing and storing large amounts of data at the enterprise level. This includes the implementation of ELN, LIMS and storage solutions.

The benefits of ATRAGENE's high-value solutions include:
• The ability to access and share heterogeneous and dispersed data.
• Integrated and enhanced access to prediction and analysis tools.
• The automation of analysis workflows and processes.
• Information capture and storage.

BIOFORDS

Agro-industry

DIRECTOR
Marc MASSON

CONTACT DETAILS
5, allée du Grand Saint-Bernard
Petite Montagne Nord
Silic 1413
F-91020 EVRY Cedex

PHONE +33 1 60 78 81 64
E-MAIL info@biofords.com
WEB SITES www.biofords.com
www.agdia.com

DATE OF FOUNDING
18th Nov. 1988

BUSINESS SECTOR
• **Agribusiness.**

FIELD OF ACTIVITY
• **Plant diagnostics & consulting in agribiotech.**

DESCRIPTION

- Diagnostics:
BIOFORDS is AGDIA's European platform for the development and sale of products for plant disease diagnostics and GMO detection in Europe, Africa and the Middle East.
With their products, BIOFORDS and AGDIA are leaders in rapid diagnostics for agriculture (Flashkits ®).

- Consulting:
BIOFORDS is also a specialist consulting company for the following themes:
- biotechnology transfer in plant science.
- plant genetics.
- biostatistics and database management.
- market investigation for new products.
- audit and program evaluation in plant R&D.

BIOFORDS also intervenes at different stages of the product development process (research, development or marketing) by offering strategic analysis and business planning services.

BIOGEMMA

Agro-industry

biogemma

DIRECTOR IN EVRY
Georges FREYSSINET

CONTACT DETAILS
1, rue Pierre Fontaine
91058 EVRY Cedex
Headquarters
1 rue Edouard Colonne
F-75001 PARIS

PHONE +33 1 60 87 29 23
E-MAIL
biogemma-evry@biogemma.com
WEB SITE www.biogemma.com

DATE OF FOUNDING
1st July 1997

BUSINESS SECTOR
• **Agro-industry, seeds.**

FIELD OF ACTIVITY
• **Genomic analysis of field crops.**

DESCRIPTION
• The genomics and bioinformatics platform located in Evry was founded in 1999 in order to develop technologies for genomic analyses in general and the implementation of DNA libraries and gene measurement technologies (DNA chips) in particular. DNA chips are available for the following species: Arabidopsis, rice, maize, wheat and oilseed rape. In parallel, a bioinformatics platform was set up to manage private- and public-sector databases and develop various types of operating and analysis software. These bioinformatics databases and tools are available to all researchers working for Biogemma and its shareholders. The platform's activities are strongly involved in France's national «Genoplante» R&D programs.

The main purpose of the results and tools developed by the platform is to help Biogemma and its shareholders create improved crops. Moreover, this platform is open to collaboration with research groups interested in these technologies.

Subject: plant biotechnology

Fields: - Genomics
- Molecular Biology
- Bioinformatics

Use: - Agriculture
- Seeds
- Plant genome

BIOMETHODES

Biomedicine / Healthcare

CEO
Marc DELCOURT

CONTACT DETAILS
5, rue Henri Desbruères
Genavenir 8
F-91030 EVRY Cedex

PHONE +33 1 60 91 21 21
E-MAIL info@biomethodes.com
WEB SITE www.biomethodes.com

DATE OF FOUNDING
6th Nov. 1997

BUSINESS SECTOR

• Optimization of enzymes and therapeutic proteins
Molecular evolution, protein engineering, high-throughput screening.

FIELD OF ACTIVITY

• Biologicals – Agro-industry - Biocatalysis.

DESCRIPTION

• Biométhodes applies its expertise in **molecular evolution and protein engineering** to the development of optimized proteins both through research partnerships and to fuel its own pipeline.

Biométhodes has developed **breakthrough technologies** to achieve rapid improvement of valuable proteins such as enzymes and therapeutic proteins:

Mutant creation:
- **Massive Mutagenesis®** is the only high-throughput, combinatorial, site-directed mutagenesis technology. It enables the generation of **large, exceptionally high-quality custom mutant libraries.**
- **Exhauseq™** delivers **all the single mutants** of a protein, each being individualized.

High-throughput selection:
- **Solexis®** rapidly selects the **soluble mutants** of an insoluble protein. It is particularly useful for enhancing the soluble expression of a **protein drug target** and facilitating its characterization.
- **THR™** is a new approach enabling **extremely rapid identification of stable variants of a given protein.** This cutting-edge technology allows quick development of **thermostable enzymes** or **therapeutic proteins with a longer half-life.**

Biométhodes' technologies have been successfully used in collaboration with industrial partners (including **GSK, bioMérieux, Sanofi–Aventis, Roquette, Adisseo** and **AB Enzymes**) and have delivered improved enzymes, antibodies, drug targets and therapeutic proteins.

Enterprise

BIOSYSTEMS International

Biomedicine / Healthcare

BioSystems INTERNATIONAL

PRESIDENT AND CSO
Laszlo TAKACS

VICE PRESIDENT BUSINESS DEVELOPMENT AND FINANCE
François LIEBAERT

CTO
Andreas GUTTMAN

CONTACT DETAILS
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91058 EVRY cedex

PHONE +33 1 60 87 89 00
+33 1 60 87 89 75
FAX +33 1 60 78 71 49
E-MAIL
biosyscontact@biosys-intl.com
WEB SITE www.biosys-intl.com

DATE OF FOUNDING
17th May 2004

BUSINESS SECTOR
• **Therapeutic research, diagnostics.**

FIELD OF ACTIVITY
• **Biomarkers discovery, validation and development.**

DESCRIPTION
• **Our mission:** BioSystems International (BSI) significantly improves drug discovery and development productivity (i.e. safer and more effective drugs at lower cost and in less time) and disease management (i.e. drug prescription justification for physicians) by bringing qualified biomarkers to the bedside.
Who we are: BSI merges pharmaceutical and diagnostics industry experience with leading scientific and technology expertise and know-how in systems biology, separation science, cutting-edge proteomics, genomics and micro/nanoscale analysis.

Our approach: BSI's proprietary *integrated and streamlined process* links the power of large-scalemonoclonal antibody technology, separation science, microfluidics, nano-volume integrated mass spectrometry and bioinformatics to query the entire plasma/serum proteome for new disease-mechanism-specific biomarkers. BSI is building a streamlined strategy to identify, validate and qualify the most promising biomarkers via a process that *includes confirmation of clinical relevance on large patient cohorts of phase II and phase III clinical trials.*

BSI partner benefits:
1) Expertise in Systems Biology technology relevant to drug and biomarker R&D as well as target discovery
2) Tools: single (e.g. ELISAs) or multiplex mAb-based clinical diagnostic assays that enable partners to monitor biomarker levels in patients involved in clinical trials

The type of partnership BSI is looking for: primarily, partnerships for which the terms of collaboration would combine cash components and intellectual property (IP) sharing.

BIOTOM

Medical Instrumentation

PRESIDENT
Marc ARTIGUE

CHIEF EXECUTIVE
Guillaume L'HERMITE

CONTACT DETAILS
Headquarters:
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
91058 EVRY Cedex
Factory: 19 rue du Bel Air
F-91090 LISSES

PHONE +33 1 60 86 74 51
FAX +33 1 72 70 36 77
E-MAIL glhermite@biotom.net
martigue@biotom.net
stephanie.le-meur@biotom.net
WEB SITE www.biotom.net

DATE OF FOUNDING
1st May 2000

BUSINESS SECTOR
• **Scientific devices.**

FIELD OF ACTIVITY
• **Design, production and commercialization of automated systems for the life sciences.**

DESCRIPTION
• BioTOM is a company that develops automated devices for the life sciences. Its know-how covers: precision mechanical engineering, electromechanical engineering, electronics, optics, industrial computing and biology. BioTOM possesses a R&D department which designs, produces and validates prototype systems and a production department which industrializes and assembles small-to-medium series of devices (20 to 200 units per year).
In the last 24 months, BioTOM has acquired ASMP (a company specializing in precision mechanical engineering) and has thus concentrated its activities on an 800-sqm production facility in the town of Lisses, near Paris.

In 2006, BioTOM's major products are as follows:
- Tiny-TOM, a robust, compact, highly modular bench robot which enables easy automation (on a very affordable budget) of a wide range of processes in biology (DNA or protein handling, pharmaceutical assays, cell biology procedures, diagnostics, etc.).



Tiny-TOM with a 48-channel head + camera.

- BioSTORE, an incubator for 600 microplates, compatible with the Tiny-TOM and which enables use of the latter in a fully automated approach (loading/unloading of plates, automatic scheduling, etc.), thus transforming the ensemble into a truly integrated platform for high-throughput screening.

- The APSI: this system is an automated platform for preparing injectable solutions for cancer therapy. Specifically designed for hospital use, the system was developed via a partnership between BioTOM, the Gustave Roussy Institute and the La Calhène company. It may become available to institutes outside the consortium in early 2007.

CELLVAX

PRESIDENT
Ming WEI

CONTACT DETAILS
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91000 EVRY

PHONE +33 1 60 87 89 00
E-MAIL
contact@cellvax-pharma.com
WEB SITE
www.cellvax-pharma.com

DATE OF FOUNDING
19th June 2001

BUSINESS SECTOR
• **Biomedicine/Healthcare.**

FIELD OF ACTIVITY
• **Service company for preclinical validation studies in the field of oncology.**

DESCRIPTION
• CellVax is a service company which provides a comprehensive range of innovative, preclinical services - enabling acceleration of the drug development process in the field of oncology.

CellVax was created by a motivated and well-matched team of scientists and experts in oncology. By offering its know-how and innovation capacity, CellVax is seeking to collaborate with public- and private-sector laboratories developing anti-cancer drugs.

CellVax's expertise is based on its know-how in the fields of molecular & cellular biology and its novel in vitro and in vivo models. These services can be extended to any laboratory involved in the anti-cancer drug development process. CellVax's service provision is well suited to the validation and development of anti-cancer drug candidates and fully validated systems such as subcutaneous and orthotopic tumor models in animals; in vitro and in vivo angiogenesis models; a novel "Nodule" system, tumor invasion tests, in vivo imaging, biodistribution studies, pharmacokinetics, etc.

We continuously endeavor to follow market trends and to satisfy our customers' specific needs worldwide. CellVax is determined to develop and enhance its national and international collaboration with public-sector labs, biotech companies and pharmaceutical businesses working in the cancer field.

CELLVIR

Biomedicine / Healthcare

BUSINESS SECTOR
• Biomedicine/Healthcare (therapeutic screening).

FIELD OF ACTIVITY
• Development of antiretroviral drugs.

DESCRIPTION
• CellVir is developing a new generation of antiretrovirals based on a novel therapeutic concept: instead of directly targeting the HIV-1 virus with drugs inhibiting the catalytic activity of viral enzymes (as do most of today's drugs), CellVir proposes to target the host-virus protein-protein interactions which have been shown to be essential for viral replication in infected cells. The advantage of this type of strategy is that it overcomes i) the resistance problems faced by current drugs, ii) issues related to viral reservoirs by targeting integration of the provirus and iii) the toxicity problems related to chronic adminsitration of today's anti-HIV compounds. The new antivirals are being developed on a completely different conceptual basis but should also complement current drug therapies.
Following the identification of novel, proprietary targets and their biological validation in Dr. Richard Benarous's laboratory at the Cochin Institute (Paris), CellVir intends to select compounds (using appropriate HTS assays) which inhibit the formation of complexes between HIV-1 viral proteins and their cognate, cellular cofactors. A first screening programme is now underway, using a 42,000-compound chemical library which is representative of a wide range of chemical structures. CellVir intends to develop the first hits up until the early development compound (EDC) phase. A first drug candidate targeting HIV-1 integrase is expected by the end of 2007 and will be out-licensed to a pharmaceutical company. Hence, licensing of the first EDC will enable CellVir to develop in-house other EDCs that will target complexes of reverse transcriptase and/or protease with the cognate, cellular cofactors required for HIV-1 replication.
CellVir is managed by a dedicated team of internationally-known scientists (specializing in basic virology research and host-pathogen molecular interactions) and acknowledged experts from the pharma industry and medicinal chemistry.

HEADS OF PROJECT
Richard PLATFORD (CEO),
Richard BENAROUS (CSO),
Jean de REGNANCOURT
(Non-executive Vice President)

CONTACT DETAILS
Département des Maladies
Infectieuses, Institut Cochin
27 rue du Faubourg St Jacques
F-75014 PARIS

PHONE +33 1 40 51 65 71
FAX +33 1 44 41 23 99
E-MAIL
benarous@cochin.inserm.fr

DATE OF FOUNDING
First semester 2006

CELOGOS

Biomedicine / Healthcare

Celogos

PRESIDENT OF THE BOARD
André ULMANN

CONTACT DETAILS
Paris Headquarters
15, rue Béranger
F-75003 PARIS
Evry Research Laboratory
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91058 EVRY

PHONE +33 1 40 33 66 06
FAX +33 1 42 77 10 60
E-MAIL aulman@celogos.fr
cpinset@celogos.fr
WEB SITE www.celogos.fr

DATE OF FOUNDING
23rd June 2001

BUSINESS SECTOR
• Therapeutic research and drug development

FIELD OF ACTIVITY
• Cell-based technologies for tissue function restoration.

DESCRIPTION
• Celogos is a biotechnology company focused on developing and producing innovative, cell-based technologies in the field of cellular medicine. The company's expertise is in tissue function restoration in general and muscle regeneration in particular.
It is estimated that the cell therapy market will reach $30 billion by 2010. By anticipating the hurdles and sensitivity surrounding embryonic (and even adult) stem cell therapies, Celogos has, since its inception, focused its research and development efforts on autologous cell therapies.
Celogos was founded in 2001 by Dr Christian Pinset, with backing from the Pasteur Institute. He spent 20 years with the French National Center for Scientific Research (CNRS) studying striated muscle.
Celogos' current mission is to develop autologous cell therapies focused on the permanent repair of small striated muscles. The first targeted indication is stress urinary incontinence, which afflicts 10 million people (mainly women) in the US, Europe and Japan.
Celogos aims to bring a pharmaceutical-grade, packaged product, (called RCD1) to the market, along with a GMP pilot lab with a plant master file and a validated logistics process (from tissue collection to transfer). RCD1 will be the first non-surgical, non-exogenous, permanent treatment for stress urinary incontinence and will offer unchallenged advantages versus the competition. The company has successfully obtained proof of concept for RCD1. In 2005, the French Agency for Health Product Safety (AFSSAPS) granted the company the first ever clearance for a clinical trial of autologous cell therapy. A Phase II clinical trial is ongoing and a phase III study is scheduled to start in Q1 2007.
Thanks to its recent alliance with Laboratoire HRA Pharma (a France-based specialty pharma company), Celogos has managed to secure the necessary funds to cover its R&D costs for the coming months and to acquire the pharmaceutical expertise critical in bridging the gap between academic research and the pharmaceutical marketplace.
In order to efficiently tap into the multi-million patient urinary incontinence market, Celogos and Laboratoire HRA Pharma will seek strategic partners, enabling RCD1 to become the benchmark treatment in urinary stress incontinence for the next decade.

CENTAURE METRIX

Medical Instrumentation

Centaure Metrix

DIRECTOR
Bernard AUVINET

SCIENTIFIC CONSULTANT
Eric BARREY

CONTACT DETAILS
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91000 EVRY

PHONE +33 1 60 87 89 71
FAX +33 1 60 87 89 99
E-MAIL
direction@centaure-metrix.com
WEB SITE
www.centaure-metrix.com

DATE OF FOUNDING
18th Oct. 2001

BUSINESS SECTOR
• **Medical Instrumentation.**

FIELD OF ACTIVITY
• **Locomotion measurement and analysis for healthcare and sport:**
. Gait analysis system for healthcare and sport.
. Ambulatory measurements of motion.
. Walking tests for rheumatology and neurology.
. Running tests for sports teams and the military.
. Training assessment of athletes and football players.
. Quantification of exercise energy expenditure for nutritional requirements.
. Equine gait analysis for early selection.
. Equine lameness analysis.
. Camel gait test for selection.
. Dog gait tests.

DESCRIPTION
• **KNOW HOW**
- Motion sensors.
- Signal analysis in biomechanics.
- Tele-assessment.
- Measurement and analysis of normal and pathological gaits in humans and animals.
- Expertise in locomotor diseases.
- Performance and athletic evaluation.

• **PRODUCTS**
- Locometrix : gait analysis system for human locomotion evaluation for medicine and sport applications.
- Equimetrix : gait analysis system for horses, dogs and camels for sporting ability evaluation, early selection and lameness assessment.

• **Customer references:**
- Pierre Fabre Pharmaceuticals : clinical tests
- French National Health Insurance Fund (CNAM), Bobigny
- Public-sector Hospitals : Paris, Toulouse, Lille, Nice
- The French rugby team
- Rehabilitation centers
- LEPHE, Genopole Evry.

Biomedicine / Healthcare

THE BIOMANUFACTURING CENTER
A GENOPOLE-MABGENE JOINT VENTURE

(In the planning stage)

PROJECT MANAGER
Alain MÉTAYER

CONTACT DETAILS
2, rue Gaston Crémieux
CP 5723
F-91057 EVRY Cedex

PHONE +33 1 60 91 32 87
+33 6 88 63 83 32
E-MAIL
alain.metayer@genopole.fr
WEB SITE www.genopole.fr

PRESIDENT OF THE BOARD
Patrick HENNO

CONTACT DETAILS
Impasse des chênes rouges
F-30319 ALÈS Cedex

PHONE +33 5 66 56 40 80
E-MAIL
mabgene@mabgene.com
WEB SITE www.mabgene.fr

BUSINESS SECTOR
• **Biopharmaceuticals/Therapeutics.**

FIELD OF ACTIVITY
• **GMP custom biomolecule production.**

DESCRIPTION
• Genopole is creating a cGMP biomanufacturing center for recombinant proteins and monoclonal antibodies. This center is being created and will be operated in partnership with the MAbgene Company, an acknowledged specialist in GMP biomolecule production. The center will open by the end of 2007.
The main objective is to offer companies and academic labs custom production of preclinical batches and batches for phase I and II clinical trials.
The biomanufacturing center will produce up to 8 batches per year, ranging from 1g to 100g of purified protein. All production operations will meet ISO 9001 standards and comply with GMP regulations.

DELPHIA LABORATOIRES

Chemistry

DELPHIA Laboratoires
La haute couture moléculaire

PRESIDENT
Bernard MORVAN

CONTACT DETAILS
32, rue Lavoisier
F-91710 VERT LE PETIT

PHONE +33 1 60 79 36 47
FAX +33 1 60 79 28 64
E-MAIL b.morvan@delphia-laboratoires.com
WEB SITE
www.delphia-laboratoires.com

DATE OF FOUNDING
1st Feb. 2000

BUSINESS SECTOR
• **Chemistry.**

FIELD OF ACTIVITY
• **Custom chemical synthesis.**

DESCRIPTION
• DELPHIA Laboratories produces molecules or building blocks in quantities of a few grams up to several kilograms. We offer a wide range of services suited to our customers' needs. Depending on the quantity of compound required, DELPHIA Laboratoires carries out multi-stage syntheses or designs a development process. This know-how makes it possible to assess industrial processes with a view to optimized production. We work with clients worldwide in the pharmacy, fine chemistry, diagnostics, cosmetics and biotech sectors.

DELPHIA Laboratories has significant experience in the following areas:
- Heterocyclic chemistry (N, S, O)
- Phosgene chemistry
- Peptides and amino acids
- Asymmetric synthesis
- Carbohydrate chemistry
- Resolution of enantiomers
- Hydrogenation
- Nitration

Enterprise

DNA THERAPEUTICS

Biomedicine / Healthcare

BUSINESS SECTOR

• Biopharmaceuticals (translational research and development of innovative therapeutics).

FIELD OF ACTIVITY

• Development of innovative therapeutics as medicines or as adjuvants to radiotherapy and chemotherapy for the treatment or prevention of cancer and other pathologies, based on "DNA bait" technology.

DESCRIPTION

• DNA Therapeutics will be spun out from four French public-sector research institutions. It aims at developing breakthrough technologies and biological drugs to provide advanced therapeutic solutions for treatment-resistant cancers. It will first in-license the core intellectual property generated by the founders from the latter's parent institutions, and will be set up in early 2006 on the outskirts of Paris with access to the radiotherapy facility at the Curie Institute, in order to fully leverage the company's unique skills.

The patents pending on **DNAbait** molecules and the **DNA Bait** technology are based on the mechanistically-targeted DNA lesion sensing, signaling and repair pathways in order to disable cancer cells' defense against existing treatments. This very recent breakthrough in molecular therapy is a paradigm shift, based on **a pathway-targeted/mechanism-oriented approach**. Hence, DNA Bait technology is exploiting a new field of molecular therapy and goes beyond gene- and protein-targeted approaches. DNAbait molecules will **temporarily neutralize the targeted DNA repair capacity in treated cells, thus providing a therapeutic window for applying radiotherapy or chemotherapy with enhanced efficacy**.

DNAbait could be a first-in-class drug for tumor radio-/chemo-resistance. It can add considerable value to existing therapies (including emerging molecular therapies), instead of risking head-to-head competition with other players.

DNA Therapeutics' strategy for cost-effective product development is to address a segment of the oncology market where there are high unmet medical needs (due to DNA repair-related treatment resistance) by combined DNAbait-radiotherapy or DNAbait-chemotherapy. DNA Therapeutics believes that it is uniquely positioned in the emerging molecular chemotherapy and radiotherapy fields to develop novel, life-saving therapeutic products for cancer treatment.

HEAD OF PROJECT

Jian Sheng SUN

CONTACT DETAILS

24, place du Président
J. F. Kennedy
F-94100 ST MAUR DES FOSSÉS

PHONE +33 6 24 75 32 39
E-MAIL sun@mnhn.fr

DATE OF FOUNDING

April 2006

DRUGABILIS

Biomedicine / Healthcare

DRUGABILIS
from molecules to drug candidates

MANAGER
Joël VACUS

CONTACT DETAILS
5, rue Jean-Baptiste Clément
F-92290 CHÂTENAY-MALABRY

PHONE +33 1 46 61 28 50
E-MAIL
joel.vacus@drugabilis.com
WEB SITE www.drugabilis.com

DATE OF FOUNDING
7th Oct. 2004

BUSINESS SECTOR

• **Pharmaceutical drugability for research: Consulting and experimental support for selection of drugable candidates and delivery systems.**

FIELD OF ACTIVITY

• **Drugability for research.**

DESCRIPTION

• DRUGABILIS is the first CRO specialized in pharmaceutical physicochemical characterization and formulation as applied to the early selection of new drug candidates. We deliver both experimental support and consulting services to our customer's research efforts by supporting the selection of drugable compounds and delivery systems.

• Experimental studies performed at DRUGABILIS deal with the physical and physicochemical characterisation of new chemical entities and delivery systems. DRUGABILIS also designs and manufactures research formulations aimed at supporting animal studies of any kind and based on any administration route.

• DRUGABILIS' consulting missions cover a large number of domains, from scientific advice for helping select preclinical development candidates to technical due diligence or the conception and design of specific methodologies for research compound evaluation.

• Based on its very comprehensive technical platform (specifically designed for discovery support), DRUGABILIS is able to create targeted experiments which address a variety of issues encountered throughout the research process. We are committed to working on minimal API amounts and meeting very tight deadlines.

• DRUGABILIS' expertise is based on years of experience of pharmaceutical research support for the selection of preclinical drug candidates and on solid knowledge of early pharmaceutical development processes and contraints, acquired in major pharmaceutical companies (Pfizer, Parke-Davis, etc.). Experiments are conducted at DRUGABILIS by very senior technical staff, all of whom have pharmaceutical industry backgrounds.

EPIXIS

Biomedicine / Healthcare

epixis

PRESIDENT
Charlotte DALBA

CONTACT DETAILS
5, rue des Wallons
F-75013 PARIS

PHONE +33 1 41 17 65 20
FAX. +33 1 42 17 65 16
E-MAIL cd@epixis.com

DATE OF FOUNDING
23rd July 2003

BUSINESS SECTOR

• **Development of immuno-therapeutics against viral infectious disease.**

FIELD OF ACTIVITY

• **Development of immunotherapeutics against Hepatitis C**

DESCRIPTION

• Development of a technology platform of vaccines and immuno therapeutics based on recombinant «virus-like particles» and neutralizing monoclonal antibodies.

FLOWGENE

Medical Instrumentation

Flowgene

CEO
Bruno de VANDIERE

CONTACT DETAILS
Rond Point du Biopole
F-63360 SAINT BEAUZIRE

PHONE +33 4 73 64 43 69
E-MAIL
b.de.vandiere@flow-gene.fr

DATE OF FOUNDING
11th Dec. 2001

BUSINESS SECTOR
• Instrumentation.

FIELD OF ACTIVITY
• Single capillary sequencing using liquid-phase capillary electrophoresis.
224 or 248 nm laser-induced fluorescence detection (native fluorescence).

DESCRIPTION
• A first project consisted in developing a DNA sequencer based on the principle of liquid-phase capillary electrophoresis (in contrast to the exclusively gel-based techniques used to date for separating bases). The use of a liquid phase for performing base separation is at the heart of Flowgene's technology: it enables the sequencing of strands of over 2000 base pairs (bps) in length. In comparison, the sequencers currently on the market are limited to 1000 bps or even 600 bps, depending on the technique used.
A base separation kit (consumable) will be developed for performing sequencing with a Flowgene-designed instrument.
• A second project consisted in developing a 224 nm laser-induced fluorescence detector. This system is particularly useful in capillary electrophoresis and HPLC and enables the detection of the native fluorescence emitted by compounds when exposed to the laser beam. The detector avoids the need to use fluorescent labels for identifying various components. Applications concern the protein and peptide fields in particular.

GENECUST

Biomedicine / Healthcare

GeneCust
Custom Services for Research

MANAGER
Fabien JOVELIN

CONTACT DETAILS
93 rue Henri Rochefort
F-91000 EVRY

PHONE +33 6 11 11 49 43
E-MAIL fjovelin@genecust.com
WEB SITE www.genecust.com

DATE OF FOUNDING
3rd March 2005

BUSINESS SECTOR
• **Custom Services.**

FIELD OF ACTIVITY
• **Custom services in proteomics and genomics.**

DESCRIPTION
• GeneCust is your prime contact for all custom services in genomics and proteomics

Our custom services:
- Recombinant adenoviruses
- Protein expression in bacterial, mammalian or baculoviral systems
- Peptide synthesis, modifications available
- Custom polyclonal or monoclonal antibodies
- Gene synthesis
- Oligonucleotide synthesis
- DNA sequencing
- Cloning, mutagenesis
- SiRNA: synthesis, vectors, adenovirus

A dedicated team for all your projects

GENE SIGNAL

Biomedicine / Healthcare

BUSINESS SECTOR
• Biomedicine/therapeutic R&D.

FIELD OF ACTIVITY
• Development of highly innovative therapeutic products on the basis of a proprietary portfolio of genes intimately involved in the regulation of angiogenesis.

DESCRIPTION
• Gene Signal is a research and development company in the field of angiogenesis. On the basis of its portfolio of over 90 genes specifically involved in the regulation of angiogenesis, Gene Signal develops and validates new, innove, therapeutic solutions for angiogenesis-related pathologies. Gene derivatives such as agonists, antagonists and recombinant proteins etc. constitute Gene Signal's product portfolio. The company is focusing its development efforts on a number of niche (and, in particular, orphan) drugs. Gene Signal's first lead has already been designated for two orphan pathologies by the EMEA (European Medicines Agency). The Phase I clinical trial has already been completed and Phase II clinical investigations are underway. In addition to the first lead, Gene Signal is currently developing five other products, covering both cardiovascular and oncological disorders.

PRESIDENT
Salman AL-MAHMOOD

CONTACT DETAILS
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91000 EVRY

PHONE +33 1 60 87 89 41/89 35
E-MAIL salman.
almahmood@wanadoo.fr

DATE OF FOUNDING
11th Feb. 2000

GENEWAVE

Medical Instrumentation

GENEWAVE

PRESIDENT
Claude WEISBUCH

CONTACT DETAILS
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91058 EVRY

PHONE +33 1 69 33 36 39
E-MAIL claude.weisbuch
@polytechnique.fr

DATE OF FOUNDING
26th Dec. 2001

BUSINESS SECTOR
• **Biophotonic instrumentation.**

FIELD OF ACTIVITY
• **Instrumentation and consumables for fluorescence biochips.**

DESCRIPTION
• Application of new concepts in theoretical and applied optics to light signal amplification on biochips, yielding considerable performance gains and opening up new biochip applications.

Products:
Fluorescence-amplifying substrates for biochips (compatible with standard spotters and readers); rapid, high-performance readers; real-time readers; integrated hybridization/reading systems.

Ongoing developments:
Ultrasensitive systems, multiwell plate readers, integrated microsystems, specific surface chemistries.



AmpliSlide™



Lame commerciale

GENODYSSEE

Biomedicine / Healthcare

BUSINESS SECTOR
• **Biotechnology: Genomics / Drug discovery.**

THERAPEUTIC TARGETS
• **Infectious disease: Hepatitis C**
• **Cancer: Melanoma / Vaccines / Neoplastic disease / Renal cell carcinoma**
• **Immunomodulation: Neoplastic disease / Vaccines adjuvant.**

DESCRIPTION
• GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of «next generation» protein products for already-developed blockbuster markets. The company has a proprietary, genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have led to generation (in the current human population) of unpredictable mutations that may confer superior therapeutic status to known human protein drugs.

Screening of this proprietary databank has yielded two lead products (natural variants of IFN alpha) and one lead candidate (a natural variant of EPO), with improved efficacy and/or safety profiles relative to currently marketed proteins. GenOdyssee's drug discovery platform is applicable to a broad variety of cytokines and growth factors including interferons, erythropoetins and interleukins and their receptors. It is also applicable to other classes of protein therapeutics, such as coagulation factors, neuropeptides, hormones and their receptors.

Low development risk profile: GenOdyssee's therapeutic products are naturally-improved variants of human IFN & EPO, which leads to a lower clinical development risk profile than artificial, genetic variants of same proteins.

PARTNERING STRATEGY/INTERESTS
GenOdyssee is looking for partnerships with pharma or «big biotech» companies with franchises in the oncology and/or virology areas and clinical development and marketing expertise. GenOdyssee is looking for long-term relationships and seeks to develop sustainable win-win solutions with its partners.

CEO
Jean-Louis ESCARY

CONTACT DETAILS
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91058 EVRY Cedex

PHONE +33 6 16 41 68 57
WEB SITE www.genodyssee.com

DATE OF FOUNDING
1st Oct. 1999

GENOMINING

Bio-informatics and Informatics

BUSINESS SECTOR
• **Bio-informatics.**

FIELD OF ACTIVITY
• **Genomining specializes in the discovery, interpretation, acquisition and exploitation of data in biology and chemistry.**

DESCRIPTION
• Genomining develops and markets tools which help analyze data in biology - *GetDB*, which allows automatic database downloading and integration, whatever the original format of the data; *Navibio* which integrates all the functions needed to automate and facilitate access to a large set of molecular biology databases; and *UVSS*, which manages large «virtual screening» pipelines on extensive computer farms, using different docking engines.
Genomining was the scientific leader of the Decrypthon I project in 2001-2002 (a major grid computing protein comparison project), together with AFM and IBM and assistance from 75,000 volunteers on the internet.
Genomining also offers service activities (such as GeneWarner, a scientific data intelligence service on annotation and proteomics) and consultancy on bioinformatics.

CEO
William SAURIN

CONTACT DETAILS
4, rue René Barthélémy
F-92120 MONTROUGE

PHONE +33 1 42 31 08 08
E-MAIL info@genomining.com
WEB SITE www.genomining.com

DATE OF FOUNDING
24th April. 2001

GENOPLANTE VALOR SAS

Agro-industry

GENOPLANTE

MEMBER OF THE EXECUTIVE BOARD
Dominique LABORDE

CONTACT DETAILS
93, rue Henri Rochefort
F-91025 EVRY Cedex

PHONE +33 1 69 47 54 00
E-MAIL laborde@genoplante.com
WEB SITE www.genoplante.com

DATE OF FOUNDING
7th Nov. 2001

BUSINESS SECTOR
• **Agro-industry.**

FIELD OF ACTIVITY
• **Activity : Plant genomics.**

DESCRIPTION
Génoplante-Valor SAS performs IP management and value enhance• ment for the results of France's «Génoplante» national public/private research program on plant genomics.

This involves:
- owning and managing all IP derived from the Génoplante R&D consortiums (patent or IP filing, defence, FTO analysis, etc.).
- negotiating in- and out-licenses on behalf of consortium members.
- granting royalty-free licenses on cash crops to developing countries.

Results:
- Bioinformatics products (software and databases) developed within Genoplante projects on wheat, maize, rice, pea, rapeseed and sunflower crops and also on the Arabidopsis model genome.
- ESTs, microarrays, BAC libraries, microsatellites, SNPs, collections of insertion mutants.

Access to the Génoplante databases and bioinformatics resources:
http://urgi.infobiogen.fr/

GENOPTICS

Medical Instrumentation

GENOPTICS
BIO INTERACTIONS

PRESIDENT OF THE BOARD OF TRUSTEES
Pierre CHAVEL

CHIEF EXECUTIVE
Philippe KEROURÉDAN

CONTACT DETAILS
Centre scientifique
Bât 503 - Plateau du Moulon
F-91403 ORSAY Cedex

PHONE +33 1 69 35 87 86
E-MAIL pkerouredan
@genoptics-spr.com
WEB SITE
www.genoptics-spr.com

DATE OF FOUNDING
7th Aug. 2001

BUSINESS SECTOR
• Biochips, biosensors.

FIELD OF ACTIVITY
• Scientific instruments allowing label-free, real-time and parallel monitoring of interactions between circulating targets and up to several hundred spots of immobilized probes on a biochip. All types of biointeractions can be detected, notably including protein-ligand, DNA-DNA, DNA-protein and oligosaccharide-protein interactions.
The technology is based on the surface plasmon resonance imaging technology (SPRi) developed at the Orsay Optics Institute in Paris, France.

DESCRIPTION
• GenOptics' mission is to develop and commercialize microarray detectors and services based on the SPRi technology.

The company commercializes two models - SPRi-Plex and SPRi-Lab.
SPRi-Lab + is an affordable instrument which is ideal for biophysics applications, amongst others.
SPRi-Plex is the appropriate model for applications in (for example) drug development screening and diagnostics research.

In addition to number of contacts with French and foreign biotech and pharmaceutical companies, contracts and collaborations have been established with:
- Centre d'Etudes du Bouchet
- Centre de Génétique Moléculaire, Gif-sur-Yvette
- ENSEA (Elite engineering school), Cergy
- INSERM, Grenoble
- CEA, Grenoble
- ENS, Cachan
- CNRS, Evry

GENOSAFE

GENOSAFE

FOUNDERS
Généthon, AFM
(the French Muscular Dystrophy Association)

CHIEF EXECUTI VE
Dr. Anne-Marie MASQUELIER

SCIENTIFIC AND TECHNICAL DIRECTOR
Dr. Christophe GAILLARD

CONTACT DETAILS
1, rue Pierre Fontaine
F-91058 EVRY Cedex

PHONE +33 1 69 36 07 57
FAX +33 1 60 78 66 20
E-MAIL contact@genosafe.com
WEB SITE www.genosafe.com

DATE OF FOUNDING
3rd Sep. 2003

BUSINESS SECTOR
• Biomedicine / Health / Service company / Safety of nucleic acid-based therapeutics.

FIELD OF ACTIVITY
• Gene therapy, cell therapy, vaccination and immunotherapy.

DESCRIPTION
• From the research stages to the clinical phases, GenoSafe provides scientific solutions for evaluating the safety of nucleic acid-based therapeutics.

Based on your project's specific characteristics, we offer the following services:
- Design and management of your complete in vivo toxicology study.
- Biodistribution analysis: assessing vector (DNA, viral/non-viral vectors and genetically modified cells) distribution, trafficking and persistence (in normal, surrounding and distal tissues, as well as at the target site) in relevant animal models.
- Characterization of the immune responses induced by your product (innate, humoral and cell-mediated immune responses).
• Quality control tests on batches of viral vectors:
• titration (viral and infectious particles)
• detection of replication-competent viruses
- risk evaluation of insertional mutagenesis.
- specific patient follow-up during clinical trial phases.

When required, studies are performed in compliance with Good Laboratory Practice (GLP).

IGNA

Biomedicine / Healthcare

BUSINESS SECTOR

• Biomedicine/Healthcare (diagnostics)/Legal medicine.

FIELD OF ACTIVITY

• IGNA («Institut Génétique Nantes Atlantique», the Nantes Atlantique Genetics Institute) is a laboratory which specializes in the analysis of human DNA in two fields of application:

- genetic fingerprinting (the laboratory is certified for genetic fingerprinting analysis by the French Ministry of Justice).
- the diagnosis of genetic diseases (via the IGNA, a medical testing laboratory certified for the diagnosis of genetic diseases by the French Ministry of the Health).

DESCRIPTION

• genetic fingerprinting: genotyping via standard STRs, mitochondrial DNA, Y chromosome haplotypes. These techniques are applied in a variety of contexts: penal proceedings, national genetic fingerprint libraries and paternity testing.

• diagnosis of the following genetic diseases: cystic fibrosis, hemochromatosis, disorders involving coagulation factors II and V, sickle-cell anemia and beta thalassemias. IGNA has a very high profile in ophthalmological genetic diseases: glaucoma and retinitis pigmentosa.

CEO
Jean-Paul MOISAN

CONTACT DETAILS
3, impasse Christophe Colomb
ZAC du Bras de Fer
F-91000 EVRY

PHONE +33 6 80 94 12 70
FAX +33 2 40 99 39 05
E-MAIL contact@igna.fr
WEB SITE www.igna.fr

DATE OF FOUNDING
6th Jun. 2004

INTEGRAGEN

Biomedicine / Healthcare

CEO
Jan MOUS

CONTACT DETAILS
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91058 EVRY Cedex

PHONE +33 1 60 91 09 00
E-MAIL contact@integragen.com
WEB SITE www.integragen.com

DATE OF FOUNDING
11th Jul. 2000

BUSINESS SECTOR

• Genetic research and diagnostics.

FIELD OF ACTIVITY

• Identification of genes causally associated with complex diseases, identification of biomarkers and the development & delivery of genetic tests and services for predictive diagnostics.

DESCRIPTION

• IntegraGen is a pioneer in the field of Personalized Medicine - developing and delivering predictive diagnostics for a range of complex diseases, through the discovery and validation of genetic markers with its unique genomic analysis technology (GenomeHIP - Genome Hybrid Identity Profiling).
Compared to other current technologies (e.g. SNP-microsatellites), GenomeHIP delivers the most powerful technology available for identifying genes causally associated with complex diseases within standard-sized patient collections.
IntegraGen develops internal research and programs to provide validated targets to the pharma and biotech industry for therapeutic development in the field of complex diseases such as autism and Type 2 diabetes.
IntegraGen also offers genome analysis services to biotech and pharma companies.
IntegraGen is developing several tests for use with patients. These tests will provide better, more rapid disease diagnosis and will help direct the choice of treatment to improve patient health outcomes.

Enterprise

IVF BIOTECH ROBOTICS

Medical Instrumentation

BUSINESS SECTOR
• Instrumentation.

FIELD OF ACTIVITY
• Design of materials for improving low-yield cell culture conditions.

DESCRIPTION
• Design of a device for controlling harmful factors which compromise the quality and growth of cultured organisms, whilst offering perfect traceability. The initial field of application is in vitro fertilization. Subsequently, the IVF BIOTECH ROBOTICS device (which incorporates an automated pipetting, transport and vision system) will be available for use in stem cell culture.

MANAGER
Daniel ATTIAS

CONTACT DETAILS
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91000 EVRY

PHONE +33 6 10 50 88 07
E-MAIL danattias@yahoo.fr

DATE OF FOUNDING
22nd Jul. 2000

LTKfarma

Biomedicine / Healthcare

FOUNDER
David KLATZMANN

HEAD OF PROJET
Laurent de NARBONNE

CONTACT DETAILS
C/O Genopole,
2, rue Gaston Crémieux
F-91057 EVRY

PHONE +33 6 80 04 03 08
E-MAIL ldenarbonne@free.fr

DATE OF FOUNDING
March 2006

BUSINESS SECTOR

• Biopharmaceuticals/Healthcare.

FIELD OF ACTIVITY

• Discovery, development and marketing of cell therapy products (derived from modified T-cells) for the treatment of leukemia and autoimmune diseases.

DESCRIPTION

• LTKfarma is a research-driven, early-stage biopharmaceutical company developing a genetic immunosuppression strategy for the application of scientific discoveries pioneered by the founding scientists: Professors David Klatzmann and François Lemoine and Dr José Cohen (CNRS/UPMC ESA 7087 Biology and Therapy of Immune Diseases Unit and the Biotherapy Service, Pierre and Marie Curie University, Pitié-Salpetrière Hospital, Paris, France). The company was incorporated in March 2006 by Laurent de Narbonne, MD, MBA (Chairman and Co-founder). The Board comprises leading businesspeople and academics with proven track records in the medical, pharmaceutical and finance industries: Tamara Joseph (former General Counsel of Transkaryotics Therapies), Leo Van Wersch (former Chairman & CEO, Procter and Gamble Pharma France), Jean-François Labbé (former President of HMR Europe and COO of ProStrakan) and Alain Clergeot (CEO, Chugai Pharma France).

LTKfarma's main objectives are to:
1. Drastically reduce mortality from graft-versus-host disease (GVHD), the main complication of allogeneic, hematopoietic stem cell transplantation (HSCT), i.e. a target figure of 5% instead of today's 20%-60%.
2. Offer a new therapeutic solution that overcomes graft shortages in HSCT for leukemia patients.
3. Offer HSCT as a therapeutic alternative with an enhanced risk/benefit ratio for patients suffering from severe forms of autoimmune diseases such as scleroderma, multiple sclerosis and rheumatoid arthritis.

MACDERMOL

Biomedicine / Healthcare

MacDermol

MANAGER
Sébastien BAI

CONTACT DETAILS
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91000 EVRY

PHONE +33 1 45 04 95 05
FAX +33 1 45 04 48 02
E-MAIL info@macdermol.com

DATE OF FOUNDING
2nd Nov. 2004

BUSINESS SECTOR
• **Biomedicine.**

FIELD OF ACTIVITY
• **Resorbable biomaterials.**

DESCRIPTION
• Production of medical devices for use in plastic surgery and orthopedic medicine. MacDermol places its experience at the service of esthetic clinics, plastic surgeons and medically-qualified esthetic practitioners.

Products:
MacDermol S and R in syringes or vials: sterile, pyrogen-free, visco-elastic gel formulations of a specific fraction of sodium hyaluronate (non-crosslinked for MacDermol S and crosslinked for MacDermol R).

MacDermol BioRevitalisation or MacDermol Biolift: pyrogen-free, visco-elastic gel formulations of a specific fraction of high-purity sodium hyaluronate, plus a vial of solvent (multivitamin-supplemented for MacDermol Biorevitalisation and amino-acid-based for MacDermol Biolift).

MAT BIOPHARMA

MAT BIOPHARMA
IMMUNO TARGETING COMPANY

PRESIDENT
Jean KADOUCHE

CONTACT DETAILS
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91058 EVRY Cedex

PHONE +33 1 60 87 89 02

DATE OF FOUNDING
15th Feb. 2000

BUSINESS SECTOR

• Biomedicine/Healthcare (therapeutic research & development).

FIELD OF ACTIVITY

• Development of therapeutic antibodies for the treatment of malignant blood diseases (such as lymphomas and leukemias) and solid tumors.

DESCRIPTION

• MAT BioPharma is a company specializing in the development of therapeutic antibodies. MAT uses several technologies: radio-immunotherapy and naked antibodies - vectors for antiproliferative or cytotoxic activities such as ADCC or CDC.
MAT has a portfolio of 5 products:
A product in phase II clinical trials: Ferritarg P, an 90Yttrium-labeled, polyclonal antiferritin antibody for the treatment of refractory Hodgkin's disease. In 2004, Ferritarg P was awarded «Orphan Medicinal Product» status for this indication by the European Medicines Agency (EMEA) . The phase II clinical protocol has been validated by the EMEA and the trial is due to start in early 2006. MAT intends to apply for temporary authorizations for patient use in 2007.

Four products in the preclinical phase:
- An 90Yttrium-labeled, chimerized, antiferritin gamma-1 monoclonal antibody for the radio-immunotherapeutic treatment of pancreatic and liver cancer.
- A chimerized, anti-CD44 gamma-4 monoclonal antibody for the treatment of acute myeloid leukemia (project funded by OSEO ANVAR, the French government's Innovation Agency)
- A bispecific (anti-CD5/antiCD32) monoclonal antibody for the treatment of the chronic lymphocytic leukemia (the STREP project, funded under the EU's FP6 RTD program)
- A chimerized gamma-1 monoclonal antibody (anti-CD71) for the treatment of the metastatic and choroid melanoma - project funded by the French government's National Research Agency *(AAP RIB 2005)*

In order to identify novel, active molecules as part of a targeted therapy approach, MAT has designed a unique high-throughput screening (HTS) platform for hybridomas and cell screening. The company been awarded «innovative company» status by OSEO ANVAR for this latter project.

Enterprise

NANOBIOGENE

Medical Instrumentation

nanobiogene

PRESIDENT
Moussa HOUMMADY

CONTACT DETAILS
Belfort Technopole
6, avenue des usines
F-90000 BELFORT

PHONE +33 3 84 28 94 36
E-MAIL
information@nanobiogene.com
WEB SITE
www.nanobiogene.com

DATE OF FOUNDING
1st Oct. 2002

BUSINESS SECTOR

• Microsystems and biomedical instrumentation, micro-nano fluidics, biochips and miniaturized laboratories.

FIELD OF ACTIVITY

• Nanobiotechnology, liquid handling, laboratory equipment.

DESCRIPTION

• NANOBIOGENE develops and commercializes nano-volume liquid handling systems and devices (as well as miniaturized laboratory equipment) for accelerating biological analysis and experimentation in sectors such as biopharmaceuticals and diagnostics. The nanotechnologies are opening up new possibilities and opportunities that will greatly benefit the healthcare and biopharmaceutical sectors. Miniaturization and the integration of biological processes at the chip level enable rapid and cost-effective large-scale experimentation.

Sectors such as biomedicine and biopharmaceuticals are facing huge demands for rapid, low-cost analysis/treatment solutions. In this respect, NANOBIOGENE is developing innovative nanofluidics systems and tools for integrating biological analysis at the chip level. The targeted applications are marker identification in genomics, proteomics and cell activities as well as molecular screening, microbiology, immunology and infectious diseases.

NAUTILUS BIOTECH

Biomedicine / Healthcare

BUSINESS SECTOR
• Therapeutic research.

FIELD OF ACTIVITY
• Development and improvement of therapeutic proteins.
In-house pipeline of proprietary products and collaboration on products from partners.

DESCRIPTION
• Nautilus Biotech develops its own portfolio of products by applying its proprietary protein engineering techniques to the development of innovative therapeutic proteins. The three most advanced products are BELEROFON“ (interferon alpha with an improved half-life for oral intake; IND in preparation), IFN-beta (improved half-life; entering regulatory preclinical development) and VITATROPIN‘ (growth hormone with improved half-life; entering regulatory preclinical development).

The company is focusing its efforts on the improvement of therapeutic proteins with high added-value. Nautilus Biotech also works with partners on protein and cell-line optimization in the areas of pharmaceutical proteins and vaccines.

CEO
Manuel VEGA

CONTACT DETAILS
1-4, rue Pierre Fontaine
F-91000 EVRY

PHONE +33 1 60 87 54 60
E-MAIL
mvega@nautilusbiotech.com
WEB SITE
www.nautilusbiotech.com

DATE OF FOUNDING
24th Jan. 2000

NOKAD

Biomedicine / Healthcare

NOKAD

MANAGER
Aymeric DUGRAY

CONTACT DETAILS
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91000 EVRY

PHONE +33 1 60 87 89 90
FAX +33 1 60 87 89 99
E-MAIL
contact@nokad-technology.com
WEB SITE
www.nokad-technology.com

DATE OF FOUNDING
21st Jan. 2004

BUSINESS SECTOR

• In vivo functional characterization, functional genomics.

FIELD OF ACTIVITY

• In vivo protein inactivation in any mammalian species (mouse, rat, rabbit, primates, etc.).

DESCRIPTION

• Nokad develops protein inactivation models and functional knock-out (KO) in all mammalian species (mouse, rat, rabbit, primates, etc.) or human disease models within just 6 months. Nokad offers functional inactivation of proteins based on specific induction of an immune response using a proprietary technology. This innovative approach helps to break through the limitations imposed by genetic KO: mice only, a time-consuming process and lack of reversibility.

Nokad's technology enables a switch from one animal strain to another (or from one species to another) within just 2 months. Observed phenotypes are stable, reversible in a controlled way and equivalent to genetic KOs. This technology allows simultaneous inactivation of several proteins (multiple KO) and is appropriate for proteins arising from alternative splicing or from gene clusters. The technology enables rapid, serial analysis of a great number of targets.

Thanks to the NOKAD's in-house know-how and tools, the company can also generate antibodies against non-immunogenic or weakly immunogenic proteins for therapeutic, diagnostic or research programs.

NOKAD also offers adenoviral overexpression services in a range of mammalian species - from the mouse to primates.

In both functional inactivation and adenoviral overexpression, phenotype studies can be specifically designed to suit customer needs.

NOVACYT

Biomedicine / Healthcare

BUSINESS SECTOR

• Biomedicine/Healthcare (diagnostics).

FIELD OF ACTIVITY

• Novacyt is developing new solutions for cytology diagnostics. The first product (due to be launched in 2007) will consist of a new, automated technology for improved, more efficient cervical cancer smear analysis.

DESCRIPTION

• Novacyt aims to become a major, worldwide player in the cytology diagnostics field by launching new-generation systems which are better suited to the market in terms of quality assurance and price.
Novacyt owns 4 international patent families. The company has wide experience of manual techniques and international validations, including FDA procedures. The company plans to automate these manual techniques by cooperating with leading companies and a network of academic researchers.

Novacyt's initial activity will consist in developing new systems dedicated to cervical cancer smear testing (detection and diagnosis). The «monolayer method» enables performance of a dual cytological and molecular biology analysis. In the medium to long term, Novacyt intends to develop an automated slide interpretation solution for cervical smears and other sample types.

HEADS OF PROJECT

CEO
Gérald ULRICH
CSO
Eric PELTIER

CONTACT DETAILS

161 bis, rue Jean Jaurès
F-92140 CLAMART

PHONE +33 1 46 42 39 96
FAX +33 1 46 42 39 96
E-MAIL
eric.peltier@novacyt.com
gerald.ulrich@novacyt.com
WEB SITE in construction

DATE OF FOUNDING

1st quarter 2006

NOVAGALI PHARMA

Biomedicine / Healthcare

BUSINESS SECTOR
• Ophthalmology/Pharmaceutical/Health & Life Sciences.

FIELD OF ACTIVITY
• Development of therapeutics for use in ophthalmology.

DESCRIPTION
• Novagali Pharma is a privately-held, ophthalmology-focused biopharmaceutical company that develops innovative products for the treatment of eye diseases.

Novagali's unique technology (Novasorb™) enables the delivery of drugs into all segments of the eye - safely and with optimal patient comfort.

Novagali's mission is to deliver the most advanced products to ophthalmologists, enabling them to provide optimal patient care. Using its proprietary cationic emulsion technology, the Novagali team designs and develops state-of-the-art ocular formulations that improve administration of ophthalmic drugs, increasing their bioavailability and efficacy, while ensuring patient comfort and ease-of-use. Novagali has built a pipeline of 8 products (at various preclinical and clinical development stages) for the treatment of the main ocular diseases, such dry eye, glaucoma and retinopathies.

PRESIDENT OF THE BOARD
Jérôme MARTINEZ

CONTACT DETAILS
Bâtiment Genavenir 4
1, rue Pierre Fontaine
F-91058 EVRY cedex

PHONE +33 1 69 87 40 20
FAX +33 1 69 87 40 30
E-MAIL novagali@novagali.com
WEB SITE www.novagali.com

DATE OF FOUNDING
8th Aug. 2000

G1J historic shareholder via Galinova

OBETHERAPY BIOTECHNOLOGY

Biomedicine / Healthcare

ObeTherapy BIOTECHNOLOGY

CEO
Itzik HAROSH

CONTACT DETAILS
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91000 EVRY

PHONE +33 1 60 87 89 04
E-MAIL iharosh@obetherapy.com
WEB SITE www.obetherapy.com

DATE OF FOUNDING
19th Jan. 2000

BUSINESS SECTOR
• **Therapeutic research.**

FIELD OF ACTIVITY
• **Drug discovery for treatment of obesity and type II diabetes.**

DESCRIPTION
• ObeTherapy Biotechnology's main goals are to:
- identify new target genes for the treatment of obesity and type II diabetes.
- validate these targets by establishing transgenic animal models.
- identify new chemical entities which can modulate the products of these target genes.
- develop these NCEs up to the preclinical phase.

The main scientific interest of the ObeTherapy Biotechnology project relates to the company's innovative approach to identifying new genes which can be used as therapeutic targets in the treatment of obesity. This approach goes against everything that is currently being done in this field: instead of looking at what genetically characterizes the obese phenotype, ObeTherapy Biotechnology is interested in the lean phenotype. This approach has made it possible to identify a family of genes implied in energy supply. These genes are high-potential therapeutic targets because they are not redundant and are very specific. If a monogenic disease preventing energy consumption can be found in lean individuals, then the gene involved in this metabolic dysfunction must have a key role and is not compensated by other mechanisms. It therefore constitutes an ideal target for the treatment of obesity. Initially, this project consists in discovering and developing therapeutic molecules directed against a first drug target, which is already validated and patented. The therapeutic molecules are identified by a novel high-throughput screening assay patented by ObeTherapy. The discovery of new therapeutic molecules and their development up to market launch are performed in close collaboration with the Zambon group (Milan, Italy). The first milestone in this collaboration was reached in April 2005, with the discovery of several chemical families of inhibitors. Optimization of these lead compounds is underway and the best molecules are due to be tested in an appropriate animal model in Q3 2006. In parallel, a new gene candidate and inhibitors have also been recently identified. The establishment of an alliance for this second target is currently under discussion.

PARTNERCHIP

Biomedicine / Healthcare

PARTNERCHIP

CEO
Pascal SOULARUE

CONTACT DETAILS
2, rue Gaston Crémieux
F-91000 EVRY

PHONE +33 1 60 87 34 62
+33 6 81 64 56 06
E-MAIL
pascal.soularue@partnerchip.fr
WEB SITE www.partnerchip.fr

DATE OF FOUNDING
25th Jan. 2005

BUSINESS SECTOR
• **Biomedicine/Healthcare (diagnostics).**

FIELD OF ACTIVITY
• **High-density microarrays.**

DESCRIPTION
• As an Affymetrix Official Service Provider, PartnerChip offers state-of-the art genomics tools and analyses.

PartnerChip enables scientists to monitor large-scale genome mapping in order to:
- quantitate known and annotated transcripts.
- understand complex biological mechanisms.
- identify new transcriptional elements.
- generate signatures and profiles.

PartnerChip also provides researchers with genotyping products for:
- performing whole genome association studies (with up to 500,000 SNPs).
- detecting heterozygosity loss.
- measuring linkage disequilibrium.
- resequencing human mitochondrial genomes.

PartnerChip offers customer services such as: experimental design support, target quality control, target hybridization on GeneChip arrays, array processing and scanning, row data production and data analysis including normalization, comparison, statistical studies, clustering, pathway involvement and data mining

Enterprise

SANOFI AVENTIS
Evry Genetics Center

Biomedicine / Healthcare

BUSINESS SECTOR
- **Pharmaceuticals/Healthcare.**

FIELD OF ACTIVITY
- **Human Genetics.**

DESCRIPTION
- Identification, annotation and validation of targets in Sanofi-Aventis's various therapeutic areas.
- Identification of genetic markers of interest for clinical development
- Genetics support for corporate research projects.

DIRECTOR
Jean-François DELEUZE

CONTACT DETAILS
2, rue Gaston Crémieux
CP 5705
F-91057 EVRY Cedex

PHONE +33 1 60 79 87 00
E-MAIL nathalie.garrabos@sanofi-aventis.com
WEB SITE
www.sanofi-aventis.com

L'essentiel c'est la santé.

SUCCEED TOGETHER IN BIOTECHNOLOGY

SEBIA

Biomedicine / Healthcare

sebia

CEO
Guy BAROUH

CONTACT DETAILS
Parc Technologique
Léonard de Vinci
CP 8010 Lisses
F-91008 EVRY Cedex

PHONE +33 1 69 89 80 80
E-MAIL sebia@sebia.com
WEB SITE www.sebia.com

DATE OF FOUNDING
October 1967

BUSINESS SECTOR
• **Biomedicine/Healthcare.**

FIELD OF ACTIVITY
• **Biological tests applied to diagnosis.**

DESCRIPTION
• SEBIA sells innovative laboratory instruments and reagents based on electrophoresis technologies.

Electrophoresis enables the separation of molecules on a support under the influence of an electric field. One of the most important of the technique's many applications concerns the analysis of proteins present in serum or other biological fluids. Hence, electrophoresis is especially useful in helping to diagnose cancer-related pathologies, searching for immune system anomalies and detecting abnormal hemoglobin species.

Since 2001, SEBIA has continually innovated in this field - notably by contributing to the development of capillary electrophoresis, which allows fully automated testing. The range of available analyses is constantly expanding.

SERIAL GENETICS

Biomedicine / Healthcare

DIRECTOR
Christophe VALAT

CONTACT DETAILS
2, rue Gaston Crémieux
F-91000 EVRY

PHONE +33 1 60 87 35 09
E-MAIL
cvalat@serialgenetics.com
WEB SITE
www.serialgenetics.com

DATE OF FOUNDING
3rd Nov. 2003

BUSINESS SECTOR
• **Biomedicine/Healthcare/Agriculture.**

FIELD OF ACTIVITY
• **Molecular diagnostics.**

DESCRIPTION
• Serial Genetics develops and commercializes molecular diagnostic kits:
- genetic diagnostic kits for cancer and hereditary diseases (includes the CE mark)
- mutation diagnostic kits for industry
- organism identification kits

All kits are based on our proprietary “HairLoop‘” probe technology
- giving powerful mutation analysis capabilities within a very simple process.

The company also commercializes ENDO-1 for mutation discovery and TILLING“. Serial Genetics is exclusively licensed by INRA/ Génoplante Valor to produce and commercialize this new, genetically engineered endonuclease: the product has greatly improved sensitivity in HT mutation discovery in humans and also enables cost-efficient plant selection in large tilling programs.
Serial Genetics is developing a line of genetic testing kits for cancer (bladder cancer) and hereditary diseases (Charcot-Marie Tooth disease, cystic fibrosis, hemochromatosis and beta thalassemia) via academic and private-sector partnerships.
We also provide on-demand kits for mutation analysis in pharmaco genomics studies and species identifications. Our customers are major pharmaceutical companies and public research institutions, as well as hospitals.

SINOVIA

Bio-informatics and Informatics

SINOVIA

MANAGER
Carlos MORENO

CONTACT DETAILS
93, rue Henri Rochefort
F-91000 EVRY

PHONE +33 1 60 87 31 20
E-MAIL contact@sinovia.com
WEB SITE www.sinovia.com

DATE OF FOUNDING
21st Apr. 1998

BUSINESS SECTOR
• **Bioinformatics/IT/data processing.**

FIELD OF ACTIVITY
• **Industrial IT networks.**

DESCRIPTION
• SINOVIA is a software house that specializes in wired or wireless network communication (ADSL, wireless technology, fiber optics) for a wide range of industrial facilities.

The company masters a range of advanced technologies and a variety of network protocols and interconnections.

SINOVIA is involved in both the civilian and military sectors (building data management systems, industrial production lines, unmanned autonomous vehicles, on-board software architecture, etc.).

SPHERGEN

Biomedicine / Healthcare

BUSINESS SECTOR
• **Drug delivery.**

FIELD OF ACTIVITY
• **Non-viral gene therapy.**

DESCRIPTION
• Sphergen is working on the elaboration of innovative, non-viral gene transfer processes which will enable the design of veterinary drugs for the treatment of currently incurable diseases.
This technology could be used for target validation purposes by R&D departments in major pharmaceutical companies.

MANAGER
Yves SCHERMAN

CONTACT DETAILS
Pépinière
Genopole® Entreprises
4, rue Pierre Fontaine
F-91000 EVRY

PHONE +33 1 49 58 95 50

DATE OF FOUNDING
1st Jul. 2004

STATLIFE

Bio-informatics and Informatics

PRESIDENT
Stéphane RAGUSA

CONTACT DETAILS
22, rue Duroc
F-75007 PARIS

PHONE +33 6 60 84 83 85
E-MAIL ragusa@noos.fr

DATE OF FOUNDING
22nd Apr. 2004

BUSINESS SECTOR
• **Healthcare, bioinformatics.**

FIELD OF ACTIVITY
• **Predictive and preventive medicine.**

DESCRIPTION
• Statlife develops software for evaluating the individual risks of major illnesses and the effects on these illnesses of various prevention strategies: changes in diet, tobacco use, treatments (hormone replacement therapy, for example).
Risk scores are calculated from prospective cohorts of between 10,000 and 100,000 individuals monitored over 8 to 15 years. These scores already include environmental and treatment-related factors and will soon benefit from integration of genetic and proteomic data.
Our clients are big pharma and health insurance companies.

SYSRA



Bio-informatics and Informatics

SYSRA
Object & Persistence

CEO
Eric VIARA

CONTACT DETAILS
30, avenue du Général Leclerc
F-91330 YERRES

PHONE +33 6 07 58 38 31
E-MAIL contact@sysra.com
WEB SITE www.sysra.com

DATE OF FOUNDING
1st Oct. 1993

BUSINESS SECTOR
• **Bio-informatics, computing.**

FIELD OF ACTIVITY
• **Specialist in database integration for molecular biology.**

DESCRIPTION
• Founded in 1993, SYSRA is an IT company specializing in object-oriented programming, relational and object-oriented databases and user interfaces.

In addition to its service provision, training and consultancy activities, SYSRA devotes significant effort to research and development. Two R&D projects are currently underway:

- the development and promotion of the EYEDB object-oriented database management system (OODBMS). EYEDB's development was initiated in 1993 and was financed mainly by equity capital and a number of collaborations with OSEO ANVAR (French Innovation Agency), the Ile-de-France Regional Council and the European Union. EYEDB is currently used in several European Union-funded academic projects and will be commercialized in the very near future.

For more information, visit the EYEDB home page:
http://www.sysra.com/eyedb

TECH INNOVATION

Medical Instrumentation

BUSINESS SECTOR
• Medical devices (prostheses and orthoses).

FIELD OF ACTIVITY
• Research and development in orthopedics: upper limb prostheses (elbow and hand) and orthoses.

DESCRIPTION
• Design, production and marketing of upper limb prostheses (elbow and hand) and hi-tech orthoses (myoelectric prostheses). The order of the prosthesis' movements is controlled by myoelectric sensors positioned on the patient's skin. These sensors detect a signal due to muscle contraction and make it possible to control three distinct movements (opening/closure of the hand, wrist rotation and elbow flexion/extension). The company has been producing a myoelectric elbow since June 2005. A myoelectric hand will be marketed in early 2006. The company also develops small medical accessories for patient assistance, in collaboration with the AFM (the French Muscular Dystrophy Association).

MANAGER
Vincent ARTIGUE

CONTACT DETAILS
36, rue du Pelvoux
CE 1455
F-91120 EVRY
COURCOURONNES

PHONE +33 1 69 47 75 88
FAX +33 1 69 47 75 77
E-MAIL vincent.artigue@techinnovation.fr
WEB SITE www.techinnovation.fr

DATE OF FOUNDING
2nd June 2000

TEXCELL

Biomedicine / Healthcare

Texcell

CEO
Bernard PLICHON

CONTACT DETAILS
Genavenir 5
1, rue Pierre Fontaine
F-91058 EVRY Cedex

PHONE +33 1 60 91 33 10
FAX +33 1 60 91 33 29
E-MAIL texcell@texcell.fr
WEB SITE www.texcell.fr

DATE OF FOUNDING
28th Jan. 2003

BUSINESS SECTOR

• Service provider to the pharmaceutical and biotech industries.

FIELD OF ACTIVITY

• Texcell was founded in order to meet industry's needs concerning international regulations on the viral safety of blood products. The company has acquired unique experience in the viral safety field for both pharmaceutical products and medical devices. In addition, Texcell has developed a new service called "ImmunoProfiling" in order to meet the needs of biotech companies seeking to analyze the humoral and cellular immune response to novel chemical and biological entities.

DESCRIPTION

• Texcell's main objective is to offer industry a viral safety approach which complies with the guidelines issued by various regulatory organizations (European Union, FDA, MHW Japan, WHO and ICH) and to provide advice and expert opinion.

Texcell is called upon to work on the following main product types: plasma derivatives, monoclonal antibodies and recombinant

THERACLION

Biomedicine / Healthcare

Theraclion
the sound therapy

PRESIDENT
François LACOSTE

CONTACT DETAILS
Theraclion S.A.S.
C/o Paris Cyber Village
204, rue de Crimée
F-75019 Paris

PHONE +33 1 55 26 43 90
FAX +33 1 55 26 43 89
E-MAIL theraclion@sfr.fr

DATE OF FOUNDING
3rd Aug. 2004

BUSINESS SECTOR

•Therapeutic medical equipment.

FIELD OF ACTIVITY

• Design & marketing of a new, non-invasive tissue treatment technique using high-intensity, focused ultrasound (HIFU).

By using an extracorporeal device to produce a localized thermal and mechanical effect, this technique produces tissue necrosis inside a targeted, accurately-delimited volume. Hence, this non-invasive and ambulatory technique (requiring no or only local anesthesia) could be used to replace surgical acts in certain pathologies.

DESCRIPTION

•The first device has been designed for the treatment of thyroid nodules.
Clinical trials started in 2003 and have already enabled safety and accuracy validations.
The ongoing Phase I clinical trials enable fine-tuning of the treatment parameters and better knowledge of the device's routine technical efficiency.

A Phase III clinical trial will start in 2006 - initially as a single-center study and then as an international, multicenter study. At the same time, the device will be industrialized. European and Japanese market launches are scheduled for late 2007. American partnerships will be sought at around this time.
In addition to maxillofacial applications, Theraclion is studying the extension of the HIFU technique to other clinical areas.
A first patent was filed in 2004 on use of the HIFU technique for the restoration of pathological changes in the vein wall which, if not treated, generally lead to the development of varicose veins.

VAXON BIOTECH

VAXON Biotech

CEO
Philippe BERTHON

SCIENTIFIC DIRECTOR
Kostas KOSMATOPOULOS

CONTACT DETAILS
2, rue Gaston Crémieux
F-91057 EVRY Cedex

PHONE +33 1 60 78 92 10
FAX +33 1 60 78 92 19
E-MAIL info@vaxon-biotech.com
WEB SITE
www.vaxon-biotech.com

DATE OF FOUNDING
8th Jan. 2004

BUSINESS SECTOR

• Biomedicine/Healthcare (thepareutic research).

FIELD OF ACTIVITY

• Vaxon Biotech is a product-driven biopharmaceutical company focusing on the discovery and development of innovative vaccines for the treatment of malignancies, including prostate, lung, breast and colon cancer.

- Vaxon Biotech is the first entrant to make vaccines with optimized cryptic peptides.
- The most advanced products, Vx-001 and Vx-006, are novel treatments for solid tumors. Vx-001 achieved phase I clinical trial mid-2004 and showed good tolerance and immune response. Vx-001 is due to enter phase II clinical trial early 2006, in hepato cellular cancer. Vx-006, should enter phase I/II clinical development in 2006 in prostate cancer.
- Vaxon Biotech develops a pipeline of products covering major HLA superfamilies to treat most cancer patients.
- Vaxon Biotech has secured a patented portfolio of products and methods in-licensed from IGR / INSERM, issued from founder's originalwork.

DESCRIPTION

• The company is based on an original discovery made by Dr. Kostas Kosmatopoulos and his team: optimized cryptic peptides. Vaxon Biotech's vaccines are intended to treat existing cancers (therapeutic vaccines) by stimulating the immune system to recognize and attack human cancer cells without harming normal cells. These vaccines target antigens overexpressed in tumor cells but present in very low quantities in normal cells. Vaxon Biotech proprietary products can be used for cellular therapy, direct subcutaneous / intramuscular vaccination in combination with adjuvants and cytokines, or integrated into specific delivery vectors, etc.

WATCHFROG

Biomedicine / Healthcare

WATCHFROG

PRESIDENT
Gregory LEMKINE

CONTACT DETAILS
Muséum National d'Histoire Naturelle
USM 501 - Case 32
CNRS UMR 5166 "Evolution des régulations endocriniennes"
7, rue Cuvier
F-75231 PARIS Cedex 5

PHONE +33 1 40 79 36 07
+33 6 16 39 81 91
E-MAIL lemkine@watchfrog.fr
WEB SITE www.watchfrog.fr

DATE OF FOUNDING
4th Nov. 2005

BUSINESS SECTOR

• **Pharmaceuticals/Environment.**

FIELD OF ACTIVITY

• **WatchFrog designs, produces and markets solutions for detecting and identifying the in vivo effects of pharmaceutical, cosmetic and chemical substances on whole vertebrates.**

DESCRIPTION

• WatchFrog's technology reveals the potential of new molecules by rapid in vivo testing using specifically-designed **amphibian** models. This test methodology combines the biological pertinence of in vivo analysis with the flexibility of **in vitro tools.**
The new generation of tests offered by WatchFrog is allied to the development of amphibian models in order to replace, reduce or refine (the «3Rs» of animal protection policies) the use of animal models. Basically, WatchFrog models will "light up" (through fluorescence emission) when a biological function is activated.
WatchFrog's adaptive technology delivers cost-effective predictability tests for human health.
WatchFrog offers a **patented transgenic technology** and **know-how** in fluorescence-based gene regulation analysis, as applied to the **Xenopus** model. This model can be used to:
• **screen therapeutic substances** (at the whole organism or specific tissue level) in secondary screening after a first stage of conventional high-throughput screening (HTS).
• detect prolonged low-dose **toxicity** (via **disruption** of **endocrine** function) for chemical and synthetic compounds and additives.
• **detect** and **quantify toxic** substances in the **environment** (e.g. drinking water, lake/river water, groundwater runoff, effluent, sludge, industrial waste, etc.).



Larvae light up in response to a molecule activating one or more biological functions. Various luminous signals enable the specificity of action in relation to an organ to be ascertained (in the image shown, nervous tissue is red and muscle tissue is green). Our system enables this activation to be located and quantified in vivo in the pertinent, easy-to-use Xenopus model..